Key stats
About GALAPAGOS NVDRN
Sector
Industry
CEO
Paulus Stoffels
Website
Headquarters
Mechelen
Founded
1999
ISIN
BRG1LPBDR002
FIGI
BBG00XX9K482
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
